Filter Results

Clinical Studies

Open

  • ALSENLITE: An Open-label Pilot Study of Senolytics for Alzheimer's Disease (ALSENLITE) Rochester, Minn.

    The purpose of this study is to measure target engagement in cerebrospinal fluid (CSF) and blood, and to establish the feasibility and safety of Dasatinib plus Quercetin treatment in adults with early stage but symptomatic Alzheimer's Disease (AD) to inform and select the best blood, CSF, urine, and other analyses to conduct in banked samples from a larger Phase 2b clinical trial.
  • ALZ-NET: Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) Rochester, Minn.

    The purpose of this study is to collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease  therapies. 
  • Biomarkers and Rates of Progression in Dementia (Bio-RaPID) Jacksonville, Fla.

    The purpose of this study is to evaluate, genetically characterize, and apply serial multimodal biomarkers in patients to determine the patient- and disease-specific factors that associate with Alzheimer disease (rpAD) and AD-related dementias (rpADRD).

Contact Us for the Latest Status

  • Biomarkers and Rates of Progression in Dementia (Bio-RaPID) Rochester, Minn.

    The purpose of this study is to evaluate, genetically characterize, and apply serial multimodal biomarkers in patients to determine the patient- and disease-specific factors that associate with Alzheimer disease (rpAD) and AD-related dementias (rpADRD).
.